Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Stuart M. Flechner, MD, is Director of Clinical Research in the Section of Renal Transplantation at Cleveland Clinic, and a Professor of Surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio.
Dr. Flechner received a BA in zoology and his MD from the University of California at Los Angeles. After completing a residency in surgery and urology at Moffitt Hospital of the University of California, San Francisco, he did a fellowship in transplantation and renal vascular surgery at Cleveland Clinic.
Dr. Flechner has held academic appointments in the Division of Organ Transplantation at the University of Texas Medical School, Houston, and in the Division of Transplantation at Stanford University School of Medicine. His academic interests include the medical and surgical management of renal transplant recipients, transplant biology and the development and application of new and innovative immunosuppressive agents. He has recently completed a sabbatical at Scripps Research Institute in California in the Department of Molecular and Experimental Medicine. He is an Associate Editor of the Journal Clinical Transplantation.
Dr. Flechner has authored more than 225 scientific articles, chapters and reviews, and is a member of the Editorial Board of Transplantation. He is also an ad hoc reviewer for 18 scientific journals in the fields of transplantation, surgery and urology. Current projects include the development of calcineurin-free immunosuppressive regimens and signature patterns of gene expression in transplanted kidneys in various stages of function.
Kidney (renal) transplantation, kidney cancer, renal failure, polycystic kidney disease, vascular disease, adrenal tumors, kidney cysts
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 12/8/2016, Dr. Flechner has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.